A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors
This is a study of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic Solid Tumors
DRUG: ATG-037|DRUG: KEYTRUDA Â®( Pembrolizumab)
Incidence of adverse events and server adverse events, Will be graded according to the NCI-CTCAE Grading Scale version 5.0., One year after last patient first dose|DLT, Number of Participants with Dose Limiting Toxicity, Up to 21 Days|MTD, Maximum tolerated dose of ATG-037, Up to 21 Days|RP2D, Recommended phase 2 dose of ATG-037, Up to 21 Days
Plasma concentration of ATG-037 and derived PK parameters, To characterize the PK/PDx of ATG-037, One year after last patient first dose|Inhibition of CD73 enzymatic activity in plasma, To evaluate the preliminary antitumor activity of ATG-037 monotherapy and combination therapy with pembrolizumab, One year after last patient first dose|ORR as per RECIST v1.1 and DOR, DCR, PFS, OS evaluated by the investigators, To evaluate the preliminary antitumor activity of ATG-037 monotherapy and combination therapy with pembrolizumab, One year after last patient first dose
Expression of related biomarkers in archived tumor tissue by IHC, To explore potential PDx markers and characterize changes of the immune microenvironment following treatment with ATG-037, One year after last patient first dose|Changes in soluble CD73 concentration in serum, To explore potential PDx markers and characterize changes of the immune microenvironment following treatment with ATG-037, One year after last patient first dose|The number and activation status of immune cells in peripheral blood, To explore potential PDx markers and characterize changes of the immune, One year after last patient first dose
This is a Phase I, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors.

Number of subjects :

1. 39-51 subjects for Dose escalation phase part 1
2. Maximum of 18 subjects or Dose escalation phase part 2
3. 24-34 subjects per Dose expansion cohort